Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 17, Issue 6, 1998, Pages 405-412

  Pechere J C ^a   Gootz, T D ^b  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; CHLAMYDOPHILA PNEUMONIAE; ENTEROCOCCUS FAECALIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; LEGIONELLA PNEUMOPHILA; MYCOPLASMA PNEUMONIAE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ANIMALS; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFECTIONS;

EID: 0031781340     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960050098     Document Type: Article

References (48)

1. Baquero F: Epidemiology and management of penicillin-resistant pneumococci. Current Opinion in Infectious Diseases (1996) 9:372-379
2. Brighty KE, Gootz TD: The chemistry and biological profile of trovafloxacin. Journal of Antimicrobial Chemotherapy (1997) 39, Supplement B:1-14
3. Gootz TD, Brighty KE: Fluoroquinolone antibacterials: SAR, mechanism of action, resistance, and clinical aspects. Medicinal Research Reviews (1996) 16:433-486
4. Wiedemann B, Heisig P: Mechanisms of quinolone resistance. Infection (1994) 22, Supplement 2:73-79
5. Hooper DC, Wolfson JS: Mechanisms of quinolone action and bacterial killing. In: Hooper DC, Wolfson JS (eds): Ouinolone antimicrobial agents. American Society for Microbiology, Washington, DC (1993), pp 53-75
6. Hoshino K, Kitamura A, Morrissey I, Sato K, Kato J, Ikeda H: Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrobial Agents and Chemotherapy (1994) 38:2623-2627
7. Belland RJ, Morrisson SG, Ison C, Huang WM: Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Molecular Microbiology (1994) 14:371-380
8. Ferrero L, Cameron B, Crouzet J: Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy (1995) 39:1554-1558
9. Gootz TD, Zaniewski R, Haskell S, Schmieder B, Tankovic J, Girard D, Courvalin P, Polzer RJ: Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrobial Agents and Chemotherapy (1996) 40:2691-2697
10. Gootz TD, Brighty KE, Anderson MR, Schmeider BJ, Haskell SL, Sutcliffe JA, Castaldi MJ, McGuirk PR: In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl)-naphthyridone antimicrobial. Diagnostic Microbiology and Infectious Disease (1994) 19:235-243
11. Cohen SP, Hachler H, Levy SB: Genetic and functional analysis of the multiple antibiotic resistance (mar) locus in Escherichia coli. Journal of Bacteriology (1993) 175:1484-1492
12. Kaatz GW, Seo SM, Ruble CA: Mechanisms of fluoroquinolone resistance in Staphylococcus aureus. Journal of Infectious Diseases (1991) 163:1080-1086
13. Trucksis M, Wolfson JS, Hooper DC: A novel locus conferring fluoroquinolone resistance in Staphylococcus aureus. Journal of Bacteriology (1991) 173:5854-5860
14. Barry AL, Brown SD, Fuchs PC: In-vitro selection of quinolone-resistant staphylococcal mutants by a single exposure to ciprofloxacin or trovafloxacin (CP-99,219). Journal of Antimicrobial Chemotherapy (1996) 38:324-327
15. Köhler T, Michéa-Hamzehpoor M, Plésiat P, Kahr AL, Pechère J-C: Differential selection of multidrug efflux systems of quinolones in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy (1997) 41:2540-2543
16. National Committee for Clinical Laboratory Standards: Standard methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standard M7-A3. NCCLS, Villanova, PA (1990)
17. Olsson-Liljequist B, Hoffman BM, Hedlund J: Activity of trovafloxacin against blood isolates of Streptococcus pneumoniae in Sweden. European Journal of Clinical Microbiology & Infectious Diseases (1996) 15:671-675
18. Sefton AM, Maskell JP, Rafay AM, Whiley A, Williams JD: The in-vitro activity of trovafloxacin, a new fluoroquinolone against gram-positive bacteria. Journal of Antimicrobial Chemotherapy (1997) 39, Supplement B:57-62
19. Felmingham D, Robbins MJ, Ingley K, Mathias I, Bhogal H, Leakey A, Ridgway GL, Grüneberg RN: In-vitro activity of trovafloxacin (CP-99,219), a new fluoroquinolone, against recent clinical isolates. Journal of Antimicrobial Chemotherapy (1997) 39, Supplement B:43-49
20. Rolston KVI, Ho DH, LeBlanc B, Streeter H, Dvorak T: Invitro activity of CP-99,219, a novel azabicyclo-naphthyridone, against clinical bacterial isolates from patients with cancer. Journal of Antimicrobial Chemotherapy (1997) 39, Supplement B:15-22
21. Urbásková P, Trupl J, Hupková H, Appelbaum PC, Jacobs MR: In vitro susceptibility of pneumococci to trovafloxacin, penicillin G, and other antimicrobial agents in the Czech Republic and Slovakia. European Journal of Clinical Microbiology & Infectious Diseases (1996) 15:686-688
22. Crokaert F, Aoun M, Duchateau V, Grenier P, Vandermies A, Klastersky J: In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens. European Journal of Clinical Microbiology & Infectious Diseases (1996) 15:696-698
23. Shonekan D, Handwerger S, Mildvan D: Comparative invitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against gram-positive bacteria. Journal of Antimicrobial Chemotherapy (1997) 39:405-409
24. Eliopoulos GM, Klimm K, Eliopoulos CT, Ferraro MJ, Moellering RC Jr: In vitro activity of CP-99,219, a new fluoroquinolone against clinical isolates of gram-positive bacteria. Antimicrobial Agents and Chemotherapy (1993) 37:366-370
25. Child J, Andrews J, Boswell F, Brenwald N, Wise R: The invitro activity of CP-99,219, a new naphthyridone antimicrobial agent: a comparison with fluoroquinolone agents. Journal of Antimicrobial Chemotherapy (1995) 35:869-876
26. Verbist L, Verhaegen J: In vitro activity of trovafloxacin versus ciprofloxacin against clinical isolates. European Journal of Clinical Microbiology & Infectious Diseases (1996) 15:683-685
27. Thomson KS, Chartrand SA, Sanders CC, Block SL: Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy (1997) 41:478-480
28. Klugman K, Wasas A: In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and -resistant Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy (1995) 36:873-874
29. Pankuch GA, Jacobs MR, Appelbaum PC: Activity of CP-99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosulfloxacin, sparfloxacin, and grepafloxacin against penicillin-susceptible and -resistant pneumococci. Journal of Antimicrobial Chemotherapy (1995) 35:230-232
30. Neu HC, Chin N: In vitro activity of the new fluoroquinolone CP-99,219. Antimicrobial Agent's and Chemotherapy (1994) 38:2615-2622
31. Briggs-Gooding B, Jones RN: In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy (1993) 37:349-353
32. Cunha BA, Qadri SMH, Ueno Y, Walters EA, Domenico P: Antibacterial activity of trovafloxacin (CP-99,219) against nosocomial gram-positive and gram-negative isolates. Journal of Antimicrobial Chemotherapy (1997) 39, Supplement B: 29-34
33. Fuchs PC, Barry AL, Brown SD: Tentative interpretative criteria for testing the susceptibility of Streptococcus pneumoniae to eight fluoroquinolones. Diagnostic Microbiology and Infectious Disease (1996) 26:23-27
34. Fuchs PC, Barry AL, Brown SD, Sewell DL: In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin. European Journal of Clinical Microbiology & Infectious Diseases (1996) 15:678-682
35. Dembry LM, Farrell PA, Orcutt DR, Gerrity LA, Andriole VT: In-vitro activity of trovafloxacin (CP-99,219 against sensitive and resistant aerobic bacteria using the standard microdilution broth method and E-test. Journal of Antimicrobial Chemotherapy (1997) 39, Supplement B:35-42
36. Mulazimoglu L, Drenning SD, Yu VL: In vitro activities of two novel oxazolidinones (U100592 and U100766), a new fluoroquinolone (trovafloxacin), and dalfopristin-quinupristin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrobial Agents and Chemotherapy (1996) 40:2428-2430
37. Coque TM, Singh KV, Murray BE: Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci. Journal of Antimicrobial Chemotherapy (1996) 37:1011-1016
38. Jones RN: In vitro antimicrobial activity of CP-99,219-99, a new 7-azabicyclonaphthyridone. Drugs (1995) 49, Supplement 21:205-207
39. Cormican MG, Jones RN: In-vitro activity of trovafloxacin (CP-99,219) tested by two methods against 150 vancomycin-resistant enterococcal isolates. Journal of Antimicrobial Chemotherapy (1996) 37:847-849
40. Freeman C, Robinson A, Cooper B, Mazens-Sullivan M, Ouintiliani R, Nightingale C: In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci. Diagnostic Microbiology and Infectious Disease (1995) 21:47-50
41. Visalli MA, Bajaksouzian S, Jacobs MR, Appelbaum PC: Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods. Antimicrobial Agents and Chemotherapy (1997) 41:1475-1478
42. Fass RJ, Barnishan J, Solomon MC, Avers LW: In vitro activities of quinolones, β-lactams, tobramycin and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli. Antimicrobial Agents and Chemotherapy (1996) 40:1412-1418
43. Roblin PM, Kutlin A, Hammerschlag MR: In vitro activity of trovafloxacin against Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy (1997) 41:2033-2034
44. Edelstein PH, Edelstein MAC, Ren J, Polzer R, Gladue RP: Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrobial Agents and Chemotherapy (1996) 40:314-319
45. Kenny GE, Cartwright FD: Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219). Antimicrobial Agents and Chemotherapy (1996) 40:1048-1049
46. Girard AE, Girard D, Gootz TD, Faiella JA, Cimochowski CR: In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae and Bacteroides fragilis. Antimicrobial Agents and Chemotherapy (1995) 39:2210-2216
47. Andrews JM, Honeybourne D, Brenwald NP, Bannerjee D, Iredale M, Cunningham D, Wise R: Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy. Journal of Antimicrobial Chemotherapy (1997) 39:797-802
48. Bedos J-P, Rieux V, Bauchet J, Muffat-Joly M, Carbon C, Azoulay-Dupuis: Efficacy of trovafloxacin against penicillin-susceptible and multiresistant strains in a mouse pneumonia model. Antimicrobial Agents and Chemotherapy (1998) 42:862-867